Literature DB >> 6199144

Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis.

E Svedmyr, I Ernberg, J Seeley, O Weiland, G Masucci, K Tsukuda, R Szigeti, M G Masucci, H Blomogren, W Berthold.   

Abstract

One patient with infectious mononucleosis (IM) was studied from the probable time of Epstein-Barr virus (EBV) infection (38 days before the onset of clinically overt disease), during the incubation and acute phases, until 6 months after clinical remission. Analysis of spontaneous outgrowth of EBV-carrying lymphoblastoid cells, by limiting dilution on feeder layer cultures, showed that virus containing B lymphocytes are already present early during the incubation period. Also low interferon serum levels were detected early after infection, and only before the onset of clinical disease. All other studied clinical laboratory and virus-associated variables were within normal range during the incubation phase, but changed to a pattern characteristic of IM in parallel to the clinical symptoms. During the acute disease EBV-associated nuclear antigen (EBNA)-positive cells could be directly detected among the lymphocytes, and antibodies to EBV antigens appeared. Lymphocytes stained by monoclonal antibodies, detecting Ia-like determinants (activated cells) and suppressor cells, increased dramatically, in parallel to a strong increase of functional suppressor cell activity, measured by inhibition of blastogenesis and PWM-induced immunoglobulin production. During the acute phase there was also a decrease of spontaneous cytotoxicity against the NK-sensitive cell line K562, while cytotoxicity (spontaneous) against an autologous EBV-positive lymphoblastoid cell line (LCL) was detected only during this phase. These reactions correlated to the presence of blasts, and the autologous reaction was exerted mainly by Fc-receptor-negative cells. Lymphokine production in response to EBV antigens was also initiated during the acute phase. During the convalescence period the serological and cellular immune parameters adjusted to the pattern of a normal EBV-seropositive person.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199144     DOI: 10.1016/0090-1229(84)90029-1

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  19 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

3.  Immune function in chronic active Epstein-Barr virus infection.

Authors:  R Kibler; D O Lucas; M J Hicks; B T Poulos; J F Jones
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

Review 4.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.

Authors:  R J Tierney; N Steven; L S Young; A B Rickinson
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

6.  Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome.

Authors:  F Merino; W Henle; P Ramírez-Duque
Journal:  J Clin Immunol       Date:  1986-07       Impact factor: 8.317

7.  EBNA size polymorphism can be used to trace Epstein-Barr virus spread within families.

Authors:  J W Gratama; M A Oosterveer; G Klein; I Ernberg
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

Review 8.  Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients.

Authors:  G Masucci; I Berkel; M G Masucci; I Ernberg; R Szigeti; F Ersoy; O Sanal; O Yegin; G Henle; W Henle
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

9.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

10.  Intensification of GVHD prophylaxis interferes with the effects of pretransplant herpes virus serology on the occurrence of grades II-IV acute graft-versus-host disease.

Authors:  J W Gratama; H vd Nat; H T Weiland; T Stijnen; W E Fibbe; J M Vossen; R Willemze; L F Verdonck
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.